128 results on '"Bordon J"'
Search Results
2. Diagnóstico por imagen de las metástasis vertebrales
- Author
-
Montoya-Bordón, J., Elvira-Ruiz, P., Carriazo-Jiménez, B., Robles-Blanco, C., Pereiro-Montbrun, F., and Rodríguez-Fernández, C.
- Published
- 2023
- Full Text
- View/download PDF
3. Activité antivirale, tolérance et pharmacocinétique du GS-1720, un nouvel INI oral hebdomadaire
- Author
-
Fichtenbaum, CJ, primary, Berhe, M., additional, Bordon, J., additional, Lalezari, J., additional, Oguchi, G., additional, Sinclair, G., additional, Wang, F., additional, Falkard, B., additional, Durand, F., additional, and Ramgopal, M., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Review of Numerical Models for Studying the Dynamic Response of Deep Foundations for the Design and Project of Wind Turbines
- Author
-
Álamo, G. M., Bordón, J. D. R., García, F., Aznárez, J. J., Padrón, L. A., Chirino, F., Maeso, O., López-Paredes, Adolfo, Series Editor, Ayuso Muñoz, José Luis, editor, Yagüe Blanco, José Luis, editor, and Capuz-Rizo, Salvador F., editor
- Published
- 2019
- Full Text
- View/download PDF
5. Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes
- Author
-
Bordon, J., Slomka, M., Gupta, R., Furmanek, S., Cavallazzi, R., Sethi, S., Niederman, M., and Ramirez, J.A.
- Published
- 2020
- Full Text
- View/download PDF
6. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response
- Author
-
Bordon, J. M., Fernandez-Botran, R., Wiemken, T. L., Peyrani, P., Uriarte, S. M., Arnold, F. W., Rodriquez-Hernandez, L., Rane, M. J., Kelley, R. R., Binford, L. E., Uppatla, S., Cavallazzi, R., Blasi, F., Aliberti, S., Restrepo, M. I., Fazeli, S., Mathur, A., Rahmani, M., Ayesu, K., and Ramirez, J.
- Published
- 2015
- Full Text
- View/download PDF
7. Cytokines and neutrophils responses in influenza pneumonia
- Author
-
Bordon, J. M., Uriarte, S., Arnold, F. W., Fernandez-Botran, R., Rane, M., Peyrani, P., Cavallazzi, R., Saad, M., and Ramirez, J.
- Published
- 2013
- Full Text
- View/download PDF
8. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients
- Author
-
Sanchez, G. V., Baird, A. M. G., Karlowsky, J. A., Master, R. N., and Bordon, J. M.
- Published
- 2014
- Full Text
- View/download PDF
9. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies
- Author
-
Ramirez, JA, Musher, DM, Evans, SE, Dela Cruz, C, Crothers, KA, Hage, CA, Aliberti, S, Anzueto, A, Arancibia, F, Arnold, F, Azoulay, E, Blasi, F, Bordon, J, Burdette, S, Cao, B, Cavallazzi, R, Chalmers, J, Charles, P, Chastre, J, Claessens, Y-E, Dean, N, Duval, X, Fartoukh, M, Feldman, C, File, T, Froes, F, Furmanek, S, Gnoni, M, Lopardo, G, Luna, C, Maruyama, T, Menendez, R, Metersky, M, Mildvan, D, Mortensen, E, Niederman, MS, Pletz, M, Rello, J, Restrepo, M, Shindo, Y, Torres, A, Waterer, G, Webb, B, Welte, T, Witzenrath, M, Wunderink, R, Ramirez, JA, Musher, DM, Evans, SE, Dela Cruz, C, Crothers, KA, Hage, CA, Aliberti, S, Anzueto, A, Arancibia, F, Arnold, F, Azoulay, E, Blasi, F, Bordon, J, Burdette, S, Cao, B, Cavallazzi, R, Chalmers, J, Charles, P, Chastre, J, Claessens, Y-E, Dean, N, Duval, X, Fartoukh, M, Feldman, C, File, T, Froes, F, Furmanek, S, Gnoni, M, Lopardo, G, Luna, C, Maruyama, T, Menendez, R, Metersky, M, Mildvan, D, Mortensen, E, Niederman, MS, Pletz, M, Rello, J, Restrepo, M, Shindo, Y, Torres, A, Waterer, G, Webb, B, Welte, T, Witzenrath, M, and Wunderink, R
- Abstract
BACKGROUND: Community-acquired pneumonia (CAP) guidelines have improved the treatment and outcomes of patients with CAP, primarily by standardization of initial empirical therapy. But current society-published guidelines exclude immunocompromised patients. RESEARCH QUESTION: There is no consensus regarding the initial treatment of immunocompromised patients with suspected CAP. STUDY DESIGN AND METHODS: This consensus document was created by a multidisciplinary panel of 45 physicians with experience in the treatment of CAP in immunocompromised patients. The Delphi survey methodology was used to reach consensus. RESULTS: The panel focused on 21 questions addressing initial management strategies. The panel achieved consensus in defining the population, site of care, likely pathogens, microbiologic workup, general principles of empirical therapy, and empirical therapy for specific pathogens. INTERPRETATION: This document offers general suggestions for the initial treatment of the immunocompromised patient who arrives at the hospital with pneumonia.
- Published
- 2020
10. Infección asociada a prótesis vascular: manejo exitoso sin retirada de prótesis
- Author
-
Martínez-Vázquez, C., Sopeña, B., Oliveira, I., Bouzas, R., Encisa, J., Ocampo, A., Gallego, C., and Bordón, J.
- Published
- 2007
- Full Text
- View/download PDF
11. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia
- Author
-
Arnold, FW, Lopardo, G, Wiemken, TL, Kelley, R, Peyrani, P, Mattingly, WA, Feldman, C, Gnoni, M, Maurici, R, Ramirez, JA, Arnold, F, Ramirez, J, Ayesu, K, File, T, Burdette, S, Blatt, S, Restrepo, M, Bordon, J, Gross, P, Musher, D, Marrie, T, Weiss, K, Roig, J, Lode, H, Welte, T, Aliberti, S, Blasi, F, Cosentini, R, Legnani, D, Franzetti, F, Montano, N, Cervi, G, Rossi, P, Voza, A, Ostrowsky, B, Pesci, A, Nava, S, Vialea, P, Galavatti, V, Patricia, A, Dimas, C, Piro, R, Viscoli, C, Torres, A, Valenti, V, Ojales, DP, Bodi, M, Porras, J, Rello, J, Menendez, R, Stolz, D, Schuetz, P, Haubitz, S, Chalmers, J, Fardon, T, Benchetrit, G, Rodriguez, E, Corral, J, Gonzalez, J, de Vedia, L, Luna, C, Martinez, J, Marzoratti, L, Rodriguez, M, Videla, A, Saavedra, F, Lopez, H, Victorio, C, Riera, F, Jimenez, P, Fernandez, P, Parada, M, Fuenzalida, AD, Riquelme, R, Barros, M, Luna, JM, Toala, I, de Morvil, GAO, Fernandez, R, Aiello, G, Alvarez, P, Soca, A, Arteta, F, Delgado, J, Levy, G, Rivero, L, Rodriguez, B, Mirabal, MP, Mateo, M, Mendoza, M, and CAPO
- Subjects
Community-acquired pneumonia ,Antimicrobial treatment ,Bacteremia ,Mortality - Abstract
Background: Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objective of this study was to define the clinical outcomes of patients with CAP and bacteremia treated with and without a macrolide. Materials and methods: Secondary analysis of the Community-Acquired Pneumonia Organization database of hospitalized patients with CAP. Patients with a positive blood culture were categorized based on the presence or absence of a macrolide in their initial antimicrobial regimen, and severity of their CAP. Outcomes included inhospital all-cause mortality, 30-day mortality, length of stay, and time to clinical stability. Results: Among 549 patients with CAP and bacteremia, 247 (45%) were treated with a macrolide and 302 (55%) were not. The primary pathogen was Streptococcus pneumoniae (74%). Poisson regression with robust error variance models were used to compare the adjusted effects of each study group on the outcomes. The unadjusted 30-day mortality was 18.4% in the macrolide group, and 29.6% in the non-macrolide group (adjusted relative risk (aRR)0.81; 95% confidence interval (CI)0.50-1.33; P = 0.41). Unadjusted in-hospital all-cause mortality was 7.3% in the macrolide group, and 18.9% in the non-macrolide group (aRR 0.54, 95% CI 0.30-0.98; P = 0.043). Length of stay and time to clinical stability were not significantly different. Conclusions: In-hospital mortality, but not 30-day mortality, was significantly better in the macrolide group. Our data support the use of a macrolide in hospitalized patients with CAP and bacteraemia.
- Published
- 2018
12. Histiocytic necrotizing lymphadenitis, Kikuchi-Fujimoto's disease, associated with systemic lupus erythemotosus
- Author
-
MARTINEZ-VAZQUEZ, C., HUGHES, G., BORDON, J., ALONSO-ALONSO, J., ANIBARRO-GARCIA, A., REDONDO-MARTINEZ, E., and TOUZA-REY, F.
- Published
- 1997
13. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia
- Author
-
Arnold, F, Lopardo, G, Wiemken, T, Kelley, R, Peyrani, P, Mattingly, W, Feldman, C, Gnoni, M, Maurici, R, Ramirez, J, Ayesu, K, File, T, Burdette, S, Blatt, S, Restrepo, M, Bordon, J, Gross, P, Musher, D, Marrie, T, Weiss, K, Roig, J, Lode, H, Welte, T, Aliberti, S, Blasi, F, Cosentini, R, Legnani, D, Franzetti, F, Montano, N, Cervi, G, Rossi, P, Voza, A, Ostrowsky, B, Pesci, A, Nava, S, Viale, P, Galavatti, V, Patricia, A, Dimas, C, Piro, R, Viscoli, C, Torres, A, Valenti, V, Ojales, D, Bodi, M, Porras, J, Rello, J, Menendez, R, Stolz, D, Schuetz, P, Haubitz, S, Chalmers, J, Fardon, T, Benchetrit, G, Rodriguez, E, Corral, J, Gonzalez, J, de Vedia, L, Luna, C, Martinez, J, Marzoratti, L, Rodriguez, M, Videla, A, Saavedra, F, Lopez, H, Victorio, C, Riera, F, Jimenez, P, Fernandez, P, Parada, M, Fuenzalida, A, Riquelme, R, Barros, M, Luna, J, Toala, I, Oze de Morvil, G, Fernandez, R, Aiello, G, Alvarez, P, Soca, A, Arteta, F, Delgado, J, Levy, G, Rivero, L, Rodriguez, B, Mirabal, M, Mateo, M, Mendoza, M, Arnold, Forest W., Lopardo, Gustavo, Wiemken, Timothy L., Kelley, Robert, Peyrani, Paula, Mattingly, William A., Feldman, Charles, Gnoni, Martin, Maurici, Rosemeri, Ramirez, Julio A., Arnold, Forest, Ramirez, Julio, Ayesu, Kwabena, File, Thomas, Burdette, Steven, Blatt, Stephen, Restrepo, Marcos, Bordon, Jose, Gross, Peter, Musher, Daniel, Marrie, Thomas, Weiss, Karl, Roig, Jorge, Lode, Harmut, Welte, Tobias, Aliberti, Stephano, Blasi, Francesco, Cosentini, Roberto, Legnani, Delfino, Franzetti, Fabio, Montano, Nicola, Cervi, Giulia, Rossi, Paolo, Voza, Antonio, Ostrowsky, Belinda, Pesci, Alberto, Nava, Stefano, Viale, Pierluigi, Galavatti, Vanni, Patricia, Aruj, Dimas, Carlos, Piro, Roberto, Viscoli, Claudio, Torres, Antoni, Valenti, Vincenzo, Ojales, Daniel Portela, Bodi, Maria, Porras, Jose, Rello, Jordi, Menendez, Rosario, Stolz, Daiana, Schuetz, Philipp, Haubitz, Sebastian, Chalmers, James, Fardon, Tom, Benchetrit, Guillermo, Rodriguez, Eduardo, Corral, Jorge, Gonzalez, Jose, de Vedia, Lautaro, Luna, Carlos, Martinez, Jorge, Marzoratti, Lucia, Rodriguez, Maria, Videla, Alejandro, Saavedra, Federico, Lopez, Horacio, Victorio, Carlos, Riera, Fernando, Jimenez, Patricio, Fernandez, Patricia, Parada, Maria, Fuenzalida, Alejandro Díaz, Riquelme, Raul, Barros, Manuel, Luna, Juan Manuel, Toala, Ivan, Oze de Morvil, Guillermo Arbo, Fernandez, Ricardo, Aiello, Gonzalo, Alvarez, Pablo, Soca, Ana, Arteta, Federico, Delgado, Jose, Levy, Gur, Rivero, Ludwig, Rodriguez, Benito, Mirabal, Mario Perez, Mateo, Marilyn, Mendoza, Myrna, Arnold, F, Lopardo, G, Wiemken, T, Kelley, R, Peyrani, P, Mattingly, W, Feldman, C, Gnoni, M, Maurici, R, Ramirez, J, Ayesu, K, File, T, Burdette, S, Blatt, S, Restrepo, M, Bordon, J, Gross, P, Musher, D, Marrie, T, Weiss, K, Roig, J, Lode, H, Welte, T, Aliberti, S, Blasi, F, Cosentini, R, Legnani, D, Franzetti, F, Montano, N, Cervi, G, Rossi, P, Voza, A, Ostrowsky, B, Pesci, A, Nava, S, Viale, P, Galavatti, V, Patricia, A, Dimas, C, Piro, R, Viscoli, C, Torres, A, Valenti, V, Ojales, D, Bodi, M, Porras, J, Rello, J, Menendez, R, Stolz, D, Schuetz, P, Haubitz, S, Chalmers, J, Fardon, T, Benchetrit, G, Rodriguez, E, Corral, J, Gonzalez, J, de Vedia, L, Luna, C, Martinez, J, Marzoratti, L, Rodriguez, M, Videla, A, Saavedra, F, Lopez, H, Victorio, C, Riera, F, Jimenez, P, Fernandez, P, Parada, M, Fuenzalida, A, Riquelme, R, Barros, M, Luna, J, Toala, I, Oze de Morvil, G, Fernandez, R, Aiello, G, Alvarez, P, Soca, A, Arteta, F, Delgado, J, Levy, G, Rivero, L, Rodriguez, B, Mirabal, M, Mateo, M, Mendoza, M, Arnold, Forest W., Lopardo, Gustavo, Wiemken, Timothy L., Kelley, Robert, Peyrani, Paula, Mattingly, William A., Feldman, Charles, Gnoni, Martin, Maurici, Rosemeri, Ramirez, Julio A., Arnold, Forest, Ramirez, Julio, Ayesu, Kwabena, File, Thomas, Burdette, Steven, Blatt, Stephen, Restrepo, Marcos, Bordon, Jose, Gross, Peter, Musher, Daniel, Marrie, Thomas, Weiss, Karl, Roig, Jorge, Lode, Harmut, Welte, Tobias, Aliberti, Stephano, Blasi, Francesco, Cosentini, Roberto, Legnani, Delfino, Franzetti, Fabio, Montano, Nicola, Cervi, Giulia, Rossi, Paolo, Voza, Antonio, Ostrowsky, Belinda, Pesci, Alberto, Nava, Stefano, Viale, Pierluigi, Galavatti, Vanni, Patricia, Aruj, Dimas, Carlos, Piro, Roberto, Viscoli, Claudio, Torres, Antoni, Valenti, Vincenzo, Ojales, Daniel Portela, Bodi, Maria, Porras, Jose, Rello, Jordi, Menendez, Rosario, Stolz, Daiana, Schuetz, Philipp, Haubitz, Sebastian, Chalmers, James, Fardon, Tom, Benchetrit, Guillermo, Rodriguez, Eduardo, Corral, Jorge, Gonzalez, Jose, de Vedia, Lautaro, Luna, Carlos, Martinez, Jorge, Marzoratti, Lucia, Rodriguez, Maria, Videla, Alejandro, Saavedra, Federico, Lopez, Horacio, Victorio, Carlos, Riera, Fernando, Jimenez, Patricio, Fernandez, Patricia, Parada, Maria, Fuenzalida, Alejandro Díaz, Riquelme, Raul, Barros, Manuel, Luna, Juan Manuel, Toala, Ivan, Oze de Morvil, Guillermo Arbo, Fernandez, Ricardo, Aiello, Gonzalo, Alvarez, Pablo, Soca, Ana, Arteta, Federico, Delgado, Jose, Levy, Gur, Rivero, Ludwig, Rodriguez, Benito, Mirabal, Mario Perez, Mateo, Marilyn, and Mendoza, Myrna
- Abstract
Background: Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objective of this study was to define the clinical outcomes of patients with CAP and bacteremia treated with and without a macrolide. Materials and methods: Secondary analysis of the Community-Acquired Pneumonia Organization database of hospitalized patients with CAP. Patients with a positive blood culture were categorized based on the presence or absence of a macrolide in their initial antimicrobial regimen, and severity of their CAP. Outcomes included in-hospital all-cause mortality, 30-day mortality, length of stay, and time to clinical stability. Results: Among 549 patients with CAP and bacteremia, 247 (45%) were treated with a macrolide and 302 (55%) were not. The primary pathogen was Streptococcus pneumoniae (74%). Poisson regression with robust error variance models were used to compare the adjusted effects of each study group on the outcomes. The unadjusted 30-day mortality was 18.4% in the macrolide group, and 29.6% in the non-macrolide group (adjusted relative risk (aRR)0.81; 95% confidence interval (CI)0.50–1.33; P = 0.41). Unadjusted in-hospital all-cause mortality was 7.3% in the macrolide group, and 18.9% in the non-macrolide group (aRR 0.54, 95% CI 0.30–0.98; P = 0.043). Length of stay and time to clinical stability were not significantly different. Conclusions: In-hospital mortality, but not 30-day mortality, was significantly better in the macrolide group. Our data support the use of a macrolide in hospitalized patients with CAP and bacteraemia
- Published
- 2018
14. Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia
- Author
-
Fernandez Botran, R, Uriarte, S, Arnold, F, Rodriguez Hernandez, L, Rane, M, Peyrani, P, Wiemken, T, Kelley, R, Uppatla, S, Cavallazzi, R, Blasi, F, Morlacchi, L, Aliberti, S, Jonsson, C, Ramirez, J, Bordon, J, Bordon, J., ALIBERTI, STEFANO, Fernandez Botran, R, Uriarte, S, Arnold, F, Rodriguez Hernandez, L, Rane, M, Peyrani, P, Wiemken, T, Kelley, R, Uppatla, S, Cavallazzi, R, Blasi, F, Morlacchi, L, Aliberti, S, Jonsson, C, Ramirez, J, Bordon, J, Bordon, J., and ALIBERTI, STEFANO
- Abstract
The objective of this study was to compare systemic and local cytokine profiles and neutrophil responses in patients with severe versus non-severe community-acquired pneumonia (CAP). Hospitalized patients with CAP were grouped according to the pneumonia severity index (PSI), as non-severe (PSI < 91 points) or severe (PSI ≥ 91 points). Blood and sputum samples were collected upon admission. Compared to non-severe CAP patients, the severe CAP group showed higher plasma levels of pro- and anti-inflammatory cytokines but in contrast, lower sputum concentrations of pro-inflammatory cytokines. Blood neutrophil functional responses were elevated in CAP patients compared to healthy controls. However, neutrophils from severe CAP patients showed reduced respiratory burst activity compared to the non-severe group. Results indicate that patients with severe CAP fail to mount a robust local pro-inflammatory response but exhibit instead a more substantial systemic inflammatory response, suggesting that a key driver of CAP severity may be the ability of the patient to generate an optimal local inflammatory response.
- Published
- 2014
15. Secondary Syphilis with Bone Involvement of the Skull: A Case Report
- Author
-
Herrera I, Herrera, primary, Huerta C, Escalona, additional, Zapico JD, Valle, additional, Bordon J, Montoya, additional, Gonzalez C, Ordonez, additional, and Guijarro B, Sobrino, additional
- Published
- 2017
- Full Text
- View/download PDF
16. Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis
- Author
-
Universitat Rovira i Virgili, Amalakuhan B., Habib S., Mangat M., Reyes L., Rodriguez A., Hinojosa C., Soni N., Gilley R., Bustamante C., Anzueto A., Levine S., Peters J., Aliberti S., Sibila O., Chalmers J., Torres A., Waterer G., Martin-Loeches I., Bordon J., Blanquer J., Sanz F., Marcos P., Rello J., Ramirez J., Solé-Violán J., Luna C., Feldman C., Witzenrath M., Wunderink R., Stolz D., Wiemken T., Shindo Y., Dela Cruz C., Orihuela C., Restrepo M., Universitat Rovira i Virgili, and Amalakuhan B., Habib S., Mangat M., Reyes L., Rodriguez A., Hinojosa C., Soni N., Gilley R., Bustamante C., Anzueto A., Levine S., Peters J., Aliberti S., Sibila O., Chalmers J., Torres A., Waterer G., Martin-Loeches I., Bordon J., Blanquer J., Sanz F., Marcos P., Rello J., Ramirez J., Solé-Violán J., Luna C., Feldman C., Witzenrath M., Wunderink R., Stolz D., Wiemken T., Shindo Y., Dela Cruz C., Orihuela C., Restrepo M.
- Abstract
To determine if serum levels of endothelial adhesion molecules were associated with the development of multiple organ failure (MOF) and in-hospital mortality in adult patients with severe sepsis.This study was a secondary data analysis of a prospective cohort study.Patients were admitted to two tertiary intensive care units in San Antonio, TX, between 2007 and 2012.Patients with severe sepsis at the time of intensive care unit (ICU) admission were enrolled. Inclusion criteria were consistent with previously published criteria for severe sepsis or septic shock in adults. Exclusion criteria included immunosuppressive medications or conditions.None.Baseline serum levels of the following endothelial cell adhesion molecules were measured within the first 72h of ICU admission: Intracellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), and Vascular Endothelial Growth Factor (VEGF). The primary and secondary outcomes were development of MOF (?2 organ dysfunction) and in-hospital mortality, respectively.Forty-eight patients were enrolled in this study, of which 29 (60%) developed MOF. Patients that developed MOF had higher levels of VCAM-1 (p=0.01) and ICAM-1 (p=0.01), but not VEGF (p=0.70) compared with patients without MOF (single organ failure only). The area under the curve (AUC) to predict MOF according to VCAM-1, ICAM-1 and VEGF was 0.71, 0.73, and 0.54, respectively. Only increased VCAM-1 levels were associated with in-hospital mortality (p=0.03). These associations were maintained even after adjusting for APACHE and SOFA scores using logistic regression.High levels of serum ICAM-1 was associated with the development of MOF. High levels of VCAM-1 was associated with both MOF and in-hospital mortality.Published by Elsevier Ltd.
- Published
- 2016
17. Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study
- Author
-
Aliberti, S, Morlacchi, L, Faverio, P, Fernandez-Botran, R, Cosentini, R, Mantero, M, Peyrani, P, Ramirez, J, Bordon, J, Blasi, F, Aliberti, Stefano, Morlacchi, Letizia Corinna, Faverio, Paola, Fernandez-Botran, Rafael, Cosentini, Roberto, Mantero, Marco, Peyrani, Paula, Ramirez, Julio, Bordon, Jose, Blasi, Francesco, Aliberti, S, Morlacchi, L, Faverio, P, Fernandez-Botran, R, Cosentini, R, Mantero, M, Peyrani, P, Ramirez, J, Bordon, J, Blasi, F, Aliberti, Stefano, Morlacchi, Letizia Corinna, Faverio, Paola, Fernandez-Botran, Rafael, Cosentini, Roberto, Mantero, Marco, Peyrani, Paula, Ramirez, Julio, Bordon, Jose, and Blasi, Francesco
- Abstract
The role and relationship between pro- and anti-inflammatory cytokines represents one of the least studied aspects of the pathogenesis of community-acquired pneumonia (CAP). The aim of the present study was to evaluate pro- and anti-inflammatory cytokines at both local (lung) and systemic (blood) levels and their relationship with the severity of the disease on admission and time for a patient to reach clinical stability during hospitalisation.
- Published
- 2016
18. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia
- Author
-
Ramirez, J, Aliberti, S, Mirsaeidi, M, Peyrani, P, Filardo, G, Amir, A, Moffett, B, Gordon, J, Blasi, F, Bordon, J, Bordon, J., ALIBERTI, STEFANO, Ramirez, J, Aliberti, S, Mirsaeidi, M, Peyrani, P, Filardo, G, Amir, A, Moffett, B, Gordon, J, Blasi, F, Bordon, J, Bordon, J., and ALIBERTI, STEFANO
- Abstract
An epidemiological link between respiratory infection and acute myocardial infarction (AMI) has been suggested, and recent data indicate that there is an association between AMI and pneumococcal community-acquired pneumonia (CAP) in hospitalized patients. The objective of this study was to investigate the association of AMI with the severity of pneumonia at hospitalization and clinical failure during hospitalization among patients with CAP
- Published
- 2008
19. Differences between local and systemic inflammatory response in patients with community acquired pneumonia (CAP)
- Author
-
Morlacchi, L, Seghezzi, S, Giunta, V, Giuliani, F, Galbiati, S, Dallari, B, Gramegna, A, Pasquale, M, Spoletini, G, Brambilla, A, Bordon, J, Blasi, F., ALIBERTI, STEFANO, Morlacchi, L, Aliberti, S, Seghezzi, S, Giunta, V, Giuliani, F, Galbiati, S, Dallari, B, Gramegna, A, Pasquale, M, Spoletini, G, Brambilla, A, Bordon, J, and Blasi, F
- Subjects
MED/17 - MALATTIE INFETTIVE ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,inflammation ,pneumonia ,citokine - Abstract
inflammation; pneumonia; citokine
- Published
- 2011
20. An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
- Author
-
ALIBERTI, STEFANO, PESCI, ALBERTO, Morlacchi, L, Gramegna, A, Dallari, B, Galbiati, S, Cosentini, R, Brambilla, A, Giuliani, F, Bordon, J, Blasi, F., Aliberti, S, Morlacchi, L, Gramegna, A, Dallari, B, Galbiati, S, Cosentini, R, Brambilla, A, Giuliani, F, Pesci, A, Bordon, J, and Blasi, F
- Subjects
inflammation ,pneumonia ,citokine - Published
- 2011
21. Enantiomer-based specificity in pheromone communication by two sympatricGnathoirichus species (Coleoptera: Scolytidae)
- Author
-
Bordon, J. H., Handley, J. R., McLean, J. A., Silverstein, R. M., Chong, L., Slessor, K. N., Johnston, B. D., and Schuler, H. R.
- Published
- 1980
- Full Text
- View/download PDF
22. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia
- Author
-
Bordon, J, Aliberti, S, Fernandez Botran, R, Uriarte, S, Rane, M, Duvvuri, P, Peyrani, P, Morlacchi, L, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, Ramirez, J., Bordon, J, Aliberti, S, Fernandez Botran, R, Uriarte, S, Rane, M, Duvvuri, P, Peyrani, P, Morlacchi, L, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, and Ramirez, J.
- Abstract
Inflammation is a double-edged sword in the outcome of pneumonia. On the one hand, an effective and timely inflammatory response is required to eliminate the invading respiratory pathogen. On the other, a toxic and prolonged inflammatory response may result in lung injury and poor outcomes, even in those receiving advanced medical care. This review focuses on recent understanding of the dynamics of the cytokine response, neutrophil activity, and responsiveness to cytokines and neutrophil lifespan as major elements of lung inflammation resulting in favorable or poor outcomes in lung infection primarily due to pneumococcus and influenza virus. Although some progress has been made in our understanding of the molecular mechanisms of the pneumonia inflammation axis composed of cytokines modulating neutrophil activation and neutrophil apoptosis, important questions remain to be answered. The degree of neutrophil activation, generation of reactive oxygen species, and the release of granule antimicrobial peptides play a key role in microbial pathogen clearance; however, prolonged neutrophil activation may contribute to lung injury and poor outcomes in pneumonia. Molecular markers of the mechanisms regulating neutrophil survival and apoptosis may help in the identification of novel therapeutic targets to modulate inflammation by inducing timely neutrophil apoptosis. A major task is to identify the mechanisms of dysregulation in inflammation leading to toxic responses, thereby targeting a biomarker and enabling timely therapies to modulate inflammation.
- Published
- 2013
23. Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes
- Author
-
Bordon, J, Aliberti, S, Duvvuri, P, Wiemken, T, Peyrani, P, Natividad, I, Caceres Lara, A, Delapenha, R, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, Ramirez, J., Bordon, J, Aliberti, S, Duvvuri, P, Wiemken, T, Peyrani, P, Natividad, I, Caceres Lara, A, Delapenha, R, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, and Ramirez, J.
- Abstract
Background: The effect of time of the first antimicrobial dose (TFAD) on the outcomes of community-acquired pneumonia (CAP) remains a controversy. Methods: This was an observational, retrospective study of consecutive adult patients hospitalized with CAP. TFAD was defined as the time in hours from arrival at the emergency department to the intravenous infusion of antimicrobial. All patients received appropriate antibiotic therapy according to available Infectious Diseases Society of America/American Thoracic Society guidelines during the time of our study. Multivariable analysis and a propensity score adjusted methodology were used to measure the association of TFAD with mortality, time to clinical stability (TCS), and length of stay in the hospital (LOS). Results: Data of 372 patients with CAP were studied. A total 29 (8.4%) patients died within 30 days of hospitalization. Our propensity-adjusted logistic regression model did not show a significant association between TFAD and mortality (p= 0.148). Patients who died received antimicrobials significantly earlier than survivors: 5.7. h vs. 7.5. h, respectively (p= 0.04). The LOS and TCS were not significantly affected by the TFAD; the LOS hazard ratio was 0.996 (95% confidence interval 0.97-1.02; p= 0.774) and the TCS hazard ratio was 1.01 (95% confidence interval 0.98-1.03; p= 0.604). Conclusions: TFAD does not seem to be associated with the clinical outcome of patients with CAP. Early TFAD should be considered as an important marker of optimal care of patients with CAP rather than as a factor predicting outcomes.
- Published
- 2013
24. Serum and hepatic biochemical evaluations of yacon (Polymnia sonchifolia) extract
- Author
-
Fernandes, A. A H [UNESP], Bordon, J. G. [UNESP], Batistella, R. F. [UNESP], Nascimento, S. M. [UNESP], Silva, M. S. [UNESP], Alves, M. J Q F [UNESP], and Universidade Estadual Paulista (Unesp)
- Subjects
liver parenchyma ,enzyme assay ,nonhuman ,plant root ,Serum protein ,animal cell ,Asteraceae ,fructan ,Fructans ,polymnia sonchifolia extract ,unclassified drug ,enzyme activity ,Metabolism ,Liver ,Medicinal plants ,medicinal plant ,biochemical composition ,plant extract ,oligosaccharide ,blood sampling ,rat ,Therapies alternatives ,aqueous solution ,alkaline phosphatase ,plant leaf - Abstract
Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:20:24Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:34:27Z : No. of bitstreams: 1 2-s2.0-0036081788.pdf: 1140575 bytes, checksum: 690fc0338650d75b9aa9355d1a94250b (MD5) Made available in DSpace on 2014-05-27T11:20:24Z (GMT). No. of bitstreams: 0 Previous issue date: 2002-01-01 Yacon is a medicinal plant, the tuberous roots of which have been thought to contain a large amount of fructan (oligosaccharides). Purpose - The aim of paper was to study the effect of aqueous extracts of yacon on biochemical parameters of clinical importance in rats. The animals (male, wistar, weighing approximately 300g) were divided in 3 groups: G1(n=8)= water control; G2(n=8)= aqueous extract of roots (0,17g/100g/day); G3(n=8)= aqueous extract of leaves (25mg/100g/day). The serum samples were obtained after 30 days, and the biochemical parameters were measured. The livers were removed and homogenized in 0,01M phosphate buffer pH 7,0 and then the supernatant fractions were used for enzyme assay. Significantly increased serum glucose was observed in G2 (206,72±91,27 mg/dL). The groups G2 and G3 rats had higher (p
- Published
- 2002
25. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia
- Author
-
Riquelme, R, Jiménez, P, Videla, A, Lopez, H, Chalmers, J, Singanayagam, A, Riquelme, M, Peyrani, P, Wiemken, T, Arbo, G, Benchetrit, G, Rioseco, M, Ayesu, K, Klotchko, A, Marzoratti, L, Raya, M, Figueroa, S, Saavedra, F, Pryluka, D, Inzunza, C, Torres, A, Alvare, P, Fernandez, P, Barros, M, Gomez, Y, Contreras, C, Rello, J, Bordon, J, Feldman, C, Arnold, F, Nakamatsu, R, Riquelme, J, Blasi, F, Aliberti, S, Cosentini, R, Lopardo, G, Gnoni, M, Welte, T, Saad, M, Guardiola, J, Ramirez, J, Videla, AJ, Rioseco, ML, ALIBERTI, STEFANO, Ramirez, J., Riquelme, R, Jiménez, P, Videla, A, Lopez, H, Chalmers, J, Singanayagam, A, Riquelme, M, Peyrani, P, Wiemken, T, Arbo, G, Benchetrit, G, Rioseco, M, Ayesu, K, Klotchko, A, Marzoratti, L, Raya, M, Figueroa, S, Saavedra, F, Pryluka, D, Inzunza, C, Torres, A, Alvare, P, Fernandez, P, Barros, M, Gomez, Y, Contreras, C, Rello, J, Bordon, J, Feldman, C, Arnold, F, Nakamatsu, R, Riquelme, J, Blasi, F, Aliberti, S, Cosentini, R, Lopardo, G, Gnoni, M, Welte, T, Saad, M, Guardiola, J, Ramirez, J, Videla, AJ, Rioseco, ML, ALIBERTI, STEFANO, and Ramirez, J.
- Abstract
BACKGROUND: Community-acquired pneumonia (CAP) severity scores can identify patients at low risk for mortality who may be suitable for ambulatory care. Here, we follow the clinical course of hospitalized patients with CAP due to 2009 H1N1 influenza. OBJECTIVE: To evaluate the role of CAP severity scores as predictors of mortality. METHODS: This was a secondary data analysis of patients hospitalized with CAP due to 2009 H1N1 influenza confirmed by reverse transcriptase polymerase chain reaction enrolled in the CAPO (Community-Acquired Pneumonia Organization) international cohort study. CAP severity scores PSI (Pneumonia Severity Index), CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥ 65 years) and CRB-65 (confusion, respiratory rate, blood pressure, age ≥ 65 years) were calculated. Actual and predicted mortality rates were compared. A total of 37 predictor variables were evaluated to define those associated with mortality. RESULTS: Data from 250 patients with CAP due to 2009 H1N1 influenza were analyzed. Patients with low predicted mortality rates (0-1.5%) had actual mortality rates ranging from 2.6% to 17.5%. Obesity and wheezing were the only novel variables associated with mortality. CONCLUSIONS: The decision to hospitalize a patient with CAP due to 2009 H1N1 influenza should not be based on current CAP severity scores, as they underestimate mortality rates in a significant number of patients. Patients with obesity or wheezing should be considered at an increased risk for mortality. © 2011 The Union.
- Published
- 2011
26. An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
- Author
-
Aliberti, S, Morlacchi, L, Gramegna, A, Dallari, B, Galbiati, S, Cosentini, R, Brambilla, A, Giuliani, F, Pesci, A, Bordon, J, Blasi, F, ALIBERTI, STEFANO, PESCI, ALBERTO, Blasi, F., Aliberti, S, Morlacchi, L, Gramegna, A, Dallari, B, Galbiati, S, Cosentini, R, Brambilla, A, Giuliani, F, Pesci, A, Bordon, J, Blasi, F, ALIBERTI, STEFANO, PESCI, ALBERTO, and Blasi, F.
- Published
- 2011
27. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia
- Author
-
Mirsaeidi, M, Peyrani, P, Aliberti, S, Filardo, G, Bordon, J, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, Ramirez, JA, Mirsaeidi, M, Peyrani, P, Aliberti, S, Filardo, G, Bordon, J, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, and Ramirez, JA
- Abstract
Background: Platelets are inflammatory cells with an important role in antimicrobial host defenses. We speculate that an abnormal platelet count may be a marker of severity in patients with community-acquired pneumonia (CAP). The objectives of this study were to evaluate if abnormal platelet count in hospitalized patients with CAP was associated with 30-day mortality and to compare platelet count and leukocyte count as predictors of 30-day mortality. Methods: We performed a retrospective cohort study of 500 consecutive patients hospitalized with CAP at the Veterans Hospital of Louisville, Kentucky, between June 2001 and March 2006 to investigate the association of platelet count and leukocyte count with 30-day mortality. Predictor variables were platelet count and leukocyte count. Abnormal platelet count was < 100,000/L (thrombocytopenia) and > 400,000/L (thrombocytosis). The outcome variable was 30-day mortality. To control for potential confounding, a propensity score that incorporated 33 variables was used. Results: Platelet count was strongly associated ( P = .0009) with 30-day mortality, whereas no association was observed for leukocyte count ( P = .5114). High platelet counts resulted in a significantly increased risk of mortality. Conclusions: Thrombocytopenia and thrombocytosis are associated with mortality in patients hospitalized with CAP. When evaluating an initial CBC test in patients with CAP, an abnormal platelet count is a better predictor of outcome than an abnormal leukocyte count. © 2010 American College of Chest Physicians.
- Published
- 2010
28. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia
- Author
-
Aliberti, S, Amir, A, Peyrani, P, Mirsaeidi, M, Allen, M, Moffett, B, Myers, J, Shaib, F, Cirino, M, Bordon, J, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, Moffett, BK, Ramirez, JA, Aliberti, S, Amir, A, Peyrani, P, Mirsaeidi, M, Allen, M, Moffett, B, Myers, J, Shaib, F, Cirino, M, Bordon, J, Blasi, F, Ramirez, J, ALIBERTI, STEFANO, Moffett, BK, and Ramirez, JA
- Abstract
The etiology of clinical failure in hospitalized patients with community-acquired pneumonia (CAP) may be related or unrelated to pulmonary infection. The objective of this study was to define the incidence, etiology, timing, and risk factors associated with clinical failures related to CAP vs those unrelated to CAP
- Published
- 2008
29. Reduced Activity Restriction Buffers the Relations Between Chronic Stress and Sympathetic Nervous System Activation
- Author
-
Ho, J. S., primary, Bordon, J., additional, Wang, V., additional, Ceglowski, J., additional, Kim, D. H., additional, Chattillion, E. A., additional, Patterson, T. L., additional, Grant, I., additional, Ziegler, M. G., additional, Mills, P. J., additional, and Mausbach, B. T., additional
- Published
- 2013
- Full Text
- View/download PDF
30. Escherichia coli antimicrobial resistance increased faster among geriatric outpatients compared with adult outpatients in the USA, 2000-10
- Author
-
Sanchez, G. V., primary, Adams, S. J. E., additional, Baird, A. M. G., additional, Master, R. N., additional, Clark, R. B., additional, and Bordon, J. M., additional
- Published
- 2013
- Full Text
- View/download PDF
31. Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study
- Author
-
Shoptaw, S, primary, Stall, R, additional, Bordon, J, additional, Kao, U, additional, Cox, C, additional, Li, X, additional, Ostrow, D G, additional, and Plankey, M W, additional
- Published
- 2012
- Full Text
- View/download PDF
32. Trimethoprim-Sulfamethoxazole May No Longer Be Acceptable for the Treatment of Acute Uncomplicated Cystitis in the United States
- Author
-
Sanchez, G. V., primary, Master, R. N., additional, and Bordon, J., additional
- Published
- 2011
- Full Text
- View/download PDF
33. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia
- Author
-
Riquelme, R., primary, Jiménez, P., additional, Videla, A. J., additional, Lopez, H., additional, Chalmers, J., additional, Singanayagam, A., additional, Riquelme, M., additional, Peyrani, P., additional, Wiemken, T., additional, Arbo, G., additional, Benchetrit, G., additional, Rioseco, M. L., additional, Ayesu, K., additional, Klotchko, A., additional, Marzoratti, L., additional, Raya, M., additional, Figueroa, S., additional, Saavedra, F., additional, Pryluka, D., additional, Inzunza, C., additional, Torres, A., additional, Alvare, P., additional, Fernandez, P., additional, Barros, M., additional, Gomez, Y., additional, Contreras, C., additional, Rello, J., additional, Bordon, J., additional, Feldman, C., additional, Arnold, F., additional, Nakamatsu, R., additional, Riquelme, J., additional, Blasi, F., additional, Aliberti, S., additional, Cosentini, R., additional, Lopardo, G., additional, Gnoni, M., additional, Welte, T., additional, Saad, M., additional, Guardiola, J., additional, and Ramirez, J., additional
- Published
- 2011
- Full Text
- View/download PDF
34. Host Finding by Heat Perception in Coeloides brunneri (Hymenoptera: Braconidae)
- Author
-
Richerson, J. V. and Bordon, J. H.
- Published
- 1974
- Full Text
- View/download PDF
35. Hemorragia pulmonar y síndrome antifosfolipídico
- Author
-
Martínez-Vázquez, C., primary, Pérez, S., additional, Bordon, J., additional, Ribera, A., additional, López, A., additional, and Ordi-Ros, J., additional
- Published
- 2004
- Full Text
- View/download PDF
36. Candida albicansEndophthalmitis in Brown Heroin Addicts: Response to Early Vitrectomy Preceded and Followed by Antifungal Therapy
- Author
-
Martinez‐Vazquez, C., primary, Fernandez‐Ulloa, J., additional, Bordon, J., additional, Sopena, B., additional, la Fuente, J. de, additional, Ocampo, A., additional, and Rubianes, M., additional
- Published
- 1998
- Full Text
- View/download PDF
37. False-Positive Rapid Plasma Reagin Tests and Anti-Cardiolipin Antibodies
- Author
-
MacLean, S. K., primary and Bordon, J., additional
- Published
- 1995
- Full Text
- View/download PDF
38. Twelve months' experience in anesthesia in a 300 bed general hospital.
- Author
-
RUMBLE JR., LESTER, GHOLSON, A. R., BORDON, J. A., FRY, E. LEE, TENENBAUM, RAYMOND, NOBLE, S. F., RUMBLE, L Jr, FRY, E L, and TENENBAUM, R
- Published
- 1961
39. Rutin ameliorates glycemic index, lipid profile and enzymatic activities in serum, heart and liver tissues of rats fed with a combination of hypercaloric diet and chronic ethanol consumption
- Author
-
Chuffa, L. G. A., Fioruci-Fontanelli, B. A., Bordon, J. G., Pires, R. B., Braga, C. P., Fábio Seiva, and Fernandes, A. A. H.
40. Compte-rendu sommaire de la 108e session extraordinaire de la Société Haute-Savoie & Valais (4–13 06 1978)
- Author
-
Charpln, André, primary, Bordon, J., additional, Farille, M., additional, Hainard, P., additional, Jacquemoud, F., additional, and Jordan, D., additional
- Published
- 1983
- Full Text
- View/download PDF
41. Parkinsonism in an HIV-infected patient with hypodense cerebral lesion
- Author
-
de la Fuente-Aguado, J., Bordón, J., Moreno, J.A., Sopeña, B., Rodriguez, A., and Martinez-Vázquez, C.
- Published
- 1996
- Full Text
- View/download PDF
42. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia
- Author
-
Forest W. Arnold, Gustavo Lopardo, Timothy L. Wiemken, Robert Kelley, Paula Peyrani, William A. Mattingly, Charles Feldman, Martin Gnoni, Rosemeri Maurici, Julio A. Ramirez, Forest Arnold, Julio Ramirez, Kwabena Ayesu, Thomas File, Steven Burdette, Stephen Blatt, Marcos Restrepo, Jose Bordon, Peter Gross, Daniel Musher, Thomas Marrie, Karl Weiss, Jorge Roig, Harmut Lode, Tobias Welte, Stephano Aliberti, Francesco Blasi, Roberto Cosentini, Delfino Legnani, Fabio Franzetti, Nicola Montano, Giulia Cervi, Paolo Rossi, Antonio Voza, Belinda Ostrowsky, Alberto Pesci, Stefano Nava, Pierluigi Viale, Vanni Galavatti, Aruj Patricia, Carlos Dimas, Roberto Piro, Claudio Viscoli, Antoni Torres, Vincenzo Valenti, Daniel Portela Ojales, Maria Bodi, Jose Porras, Jordi Rello, Rosario Menendez, Daiana Stolz, Philipp Schuetz, Sebastian Haubitz, James Chalmers, Tom Fardon, Guillermo Benchetrit, Eduardo Rodriguez, Jorge Corral, Jose Gonzalez, Lautaro de Vedia, Carlos Luna, Jorge Martinez, Lucia Marzoratti, Maria Rodriguez, Alejandro Videla, Federico Saavedra, Horacio Lopez, Carlos Victorio, Fernando Riera, Patricio Jimenez, Patricia Fernandez, Maria Parada, Alejandro Díaz Fuenzalida, Raul Riquelme, Manuel Barros, Juan Manuel Luna, Ivan Toala, Guillermo Arbo Oze de Morvil, Ricardo Fernandez, Gonzalo Aiello, Pablo Alvarez, Ana Soca, Federico Arteta, Jose Delgado, Gur Levy, Ludwig Rivero, Benito Rodriguez, Mario Perez Mirabal, Marilyn Mateo, Myrna Mendoza, Arnold, F, Lopardo, G, Wiemken, T, Kelley, R, Peyrani, P, Mattingly, W, Feldman, C, Gnoni, M, Maurici, R, Ramirez, J, Ayesu, K, File, T, Burdette, S, Blatt, S, Restrepo, M, Bordon, J, Gross, P, Musher, D, Marrie, T, Weiss, K, Roig, J, Lode, H, Welte, T, Aliberti, S, Blasi, F, Cosentini, R, Legnani, D, Franzetti, F, Montano, N, Cervi, G, Rossi, P, Voza, A, Ostrowsky, B, Pesci, A, Nava, S, Viale, P, Galavatti, V, Patricia, A, Dimas, C, Piro, R, Viscoli, C, Torres, A, Valenti, V, Ojales, D, Bodi, M, Porras, J, Rello, J, Menendez, R, Stolz, D, Schuetz, P, Haubitz, S, Chalmers, J, Fardon, T, Benchetrit, G, Rodriguez, E, Corral, J, Gonzalez, J, de Vedia, L, Luna, C, Martinez, J, Marzoratti, L, Rodriguez, M, Videla, A, Saavedra, F, Lopez, H, Victorio, C, Riera, F, Jimenez, P, Fernandez, P, Parada, M, Fuenzalida, A, Riquelme, R, Barros, M, Luna, J, Toala, I, Oze de Morvil, G, Fernandez, R, Aiello, G, Alvarez, P, Soca, A, Arteta, F, Delgado, J, Levy, G, Rivero, L, Rodriguez, B, Mirabal, M, Mateo, M, and Mendoza, M
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Databases, Factual ,Community-acquired pneumonia ,Antimicrobial treatment ,Bacteremia ,Kaplan-Meier Estimate ,medicine.disease_cause ,Severity of Illness Index ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Internal medicine ,Streptococcus pneumoniae ,medicine ,Pneumonia, Bacterial ,Humans ,030212 general & internal medicine ,Poisson regression ,Hospital Mortality ,Mortality ,Aged ,Aged, 80 and over ,business.industry ,Length of Stay ,Middle Aged ,medicine.disease ,Confidence interval ,Anti-Bacterial Agents ,Community-Acquired Infections ,Pneumonia ,Regimen ,Treatment Outcome ,030228 respiratory system ,Relative risk ,symbols ,Drug Therapy, Combination ,Female ,Macrolides ,business - Abstract
Background Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objective of this study was to define the clinical outcomes of patients with CAP and bacteremia treated with and without a macrolide. Materials and methods Secondary analysis of the Community-Acquired Pneumonia Organization database of hospitalized patients with CAP. Patients with a positive blood culture were categorized based on the presence or absence of a macrolide in their initial antimicrobial regimen, and severity of their CAP. Outcomes included in-hospital all-cause mortality, 30-day mortality, length of stay, and time to clinical stability. Results Among 549 patients with CAP and bacteremia, 247 (45%) were treated with a macrolide and 302 (55%) were not. The primary pathogen was Streptococcus pneumoniae (74%). Poisson regression with robust error variance models were used to compare the adjusted effects of each study group on the outcomes. The unadjusted 30-day mortality was 18.4% in the macrolide group, and 29.6% in the non-macrolide group (adjusted relative risk (aRR)0.81; 95% confidence interval (CI)0.50–1.33; P = 0.41). Unadjusted in-hospital all-cause mortality was 7.3% in the macrolide group, and 18.9% in the non-macrolide group (aRR 0.54, 95% CI 0.30–0.98; P = 0.043). Length of stay and time to clinical stability were not significantly different. Conclusions In-hospital mortality, but not 30-day mortality, was significantly better in the macrolide group. Our data support the use of a macrolide in hospitalized patients with CAP and bacteraemia.
- Published
- 2018
43. Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes
- Author
-
Inez Natividad, Julio A. Ramirez, Jose Bordon, Paula Peyrani, Stefano Aliberti, Alfredo Caceres-Lara, Robert Delapenha, Francesco Blasi, Timothy L. Wiemken, Padmaraj Duvvuri, Bordon, J, Aliberti, S, Duvvuri, P, Wiemken, T, Peyrani, P, Natividad, I, Caceres Lara, A, Delapenha, R, Blasi, F, and Ramirez, J
- Subjects
Male ,Microbiology (medical) ,Emergency Medical Services ,medicine.medical_specialty ,Community-acquired pneumonia ,Critical Care ,pneumonia, community-acquired pneumonia, antibiotic, outcomes ,Outcomes ,Logistic regression ,Internal medicine ,Pneumonia, Bacterial ,medicine ,Humans ,Mortality ,Intensive care medicine ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,business.industry ,Hazard ratio ,Standard of Care ,Retrospective cohort study ,General Medicine ,Emergency department ,Length of Stay ,Middle Aged ,medicine.disease ,Confidence interval ,Anti-Bacterial Agents ,Community-Acquired Infections ,Time to first antibiotic dose ,Pneumonia ,MED/17 - MALATTIE INFETTIVE ,Treatment Outcome ,Infectious Diseases ,Multivariate Analysis ,Propensity score matching ,Female ,MED/09 - MEDICINA INTERNA ,business - Abstract
Summary Background The effect of time of the first antimicrobial dose (TFAD) on the outcomes of community-acquired pneumonia (CAP) remains a controversy. Methods This was an observational, retrospective study of consecutive adult patients hospitalized with CAP. TFAD was defined as the time in hours from arrival at the emergency department to the intravenous infusion of antimicrobial. All patients received appropriate antibiotic therapy according to available Infectious Diseases Society of America/American Thoracic Society guidelines during the time of our study. Multivariable analysis and a propensity score adjusted methodology were used to measure the association of TFAD with mortality, time to clinical stability (TCS), and length of stay in the hospital (LOS). Results Data of 372 patients with CAP were studied. A total 29 (8.4%) patients died within 30 days of hospitalization. Our propensity-adjusted logistic regression model did not show a significant association between TFAD and mortality ( p =0.148). Patients who died received antimicrobials significantly earlier than survivors: 5.7h vs. 7.5h, respectively ( p =0.04). The LOS and TCS were not significantly affected by the TFAD; the LOS hazard ratio was 0.996 (95% confidence interval 0.97–1.02; p =0.774) and the TCS hazard ratio was 1.01 (95% confidence interval 0.98–1.03; p =0.604). Conclusions TFAD does not seem to be associated with the clinical outcome of patients with CAP. Early TFAD should be considered as an important marker of optimal care of patients with CAP rather than as a factor predicting outcomes.
- Published
- 2013
44. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia
- Author
-
Jose Bordon, Paula Peyrani, Letizia Corinna Morlacchi, Silvia M. Uriarte, Rafael Fernandez-Botran, Stefano Aliberti, Julio A. Ramirez, Madhavi J. Rane, Francesco Blasi, Padmaraj Duvvuri, Bordon, J, Aliberti, S, Fernandez Botran, R, Uriarte, S, Rane, M, Duvvuri, P, Peyrani, P, Morlacchi, L, Blasi, F, and Ramirez, J
- Subjects
Microbiology (medical) ,citokines ,Neutrophils ,Antimicrobial peptides ,Neutrophil apoptosis ,Apoptosis ,Inflammation ,Biology ,Lung injury ,Neutrophil Activation ,Virus ,medicine ,Humans ,chemistry.chemical_classification ,Reactive oxygen species ,Lung ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,Pneumonia ,General Medicine ,MED/17 - MALATTIE INFETTIVE ,Infectious Diseases ,medicine.anatomical_structure ,chemistry ,inflammation ,Immunology ,Cytokines ,medicine.symptom ,Reactive Oxygen Species - Abstract
SummaryInflammation is a double-edged sword in the outcome of pneumonia. On the one hand, an effective and timely inflammatory response is required to eliminate the invading respiratory pathogen. On the other, a toxic and prolonged inflammatory response may result in lung injury and poor outcomes, even in those receiving advanced medical care. This review focuses on recent understanding of the dynamics of the cytokine response, neutrophil activity, and responsiveness to cytokines and neutrophil lifespan as major elements of lung inflammation resulting in favorable or poor outcomes in lung infection primarily due to pneumococcus and influenza virus. Although some progress has been made in our understanding of the molecular mechanisms of the pneumonia inflammation axis composed of cytokines modulating neutrophil activation and neutrophil apoptosis, important questions remain to be answered. The degree of neutrophil activation, generation of reactive oxygen species, and the release of granule antimicrobial peptides play a key role in microbial pathogen clearance; however, prolonged neutrophil activation may contribute to lung injury and poor outcomes in pneumonia. Molecular markers of the mechanisms regulating neutrophil survival and apoptosis may help in the identification of novel therapeutic targets to modulate inflammation by inducing timely neutrophil apoptosis. A major task is to identify the mechanisms of dysregulation in inflammation leading to toxic responses, thereby targeting a biomarker and enabling timely therapies to modulate inflammation.
- Published
- 2013
45. Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study
- Author
-
Stefano Aliberti, Rafael Fernandez-Botran, Julio A. Ramirez, Paula Peyrani, Jose Bordon, Roberto Cosentini, Paola Faverio, Letizia Corinna Morlacchi, Francesco Blasi, Marco Mantero, Aliberti, S, Morlacchi, L, Faverio, P, Fernandez-Botran, R, Cosentini, R, Mantero, M, Peyrani, P, Ramirez, J, Bordon, J, and Blasi, F
- Subjects
0301 basic medicine ,Serum ,medicine.medical_specialty ,Inflammatory cytokine ,Community-acquired pneumonia ,medicine.medical_treatment ,Gastroenterology ,Proinflammatory cytokine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Exhaled breath condensate ,medicine ,Prospective cohort study ,Inflammation ,business.industry ,Research ,Interleukin ,General Medicine ,medicine.disease ,Inflammatory cytokines ,Pneumonia ,030104 developmental biology ,Cytokine ,030228 respiratory system ,Immunology ,business ,Cohort study - Abstract
Background The role and relationship between pro- and anti-inflammatory cytokines represents one of the least studied aspects of the pathogenesis of community-acquired pneumonia (CAP). The aim of the present study was to evaluate pro- and anti-inflammatory cytokines at both local (lung) and systemic (blood) levels and their relationship with the severity of the disease on admission and time for a patient to reach clinical stability during hospitalisation. Methods This was an observational, prospective, cohort study of hospitalised patients with a diagnosis of CAP at the IRCCS Policlinico Hospital, Milan, Italy, between April 2010 and January 2012. Ten pro-inflammatory cytokines (interleukin [IL]-1, IL-1α, IL-1β, IL-2, IL-6, IL-8, tumor necrosis factor [TNF]α and interferon [IFN]γ) and anti-inflammatory cytokines (IL-4 and IL-10) were measured in both serum and exhaled breath condensate within 24 h after hospital admission. Results A total of 74 patients (median age: 76 years; gender: 61 % male) were enrolled. The anti- to pro-inflammatory cytokine ratio was reduced in patients with severe disease on admission and prolonged time to reach clinical stability. This was due to lower levels of anti-inflammatory cytokines in the exhaled breath condensate and higher levels of pro-inflammatory cytokines in serum. Conclusions Dis-regulation between pro- and anti-inflammatory pathways might be a part of the pathogenic mechanisms that lead to severe infection and worse early clinical outcomes in CAP patients. Electronic supplementary material The online version of this article (doi:10.1186/s41479-016-0009-7) contains supplementary material, which is available to authorized users.
- Published
- 2016
46. Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia
- Author
-
Stefano Aliberti, Silvia M. Uriarte, Rafael Fernandez-Botran, Srinivas Uppatla, Julio A. Ramirez, Lisandra Rodriguez-Hernandez, Colleen B. Jonsson, Paula Peyrani, Jose Bordon, Madhavi J. Rane, Forest W Arnold, Robert Kelley, Rodrigo Cavallazzi, Francesco Blasi, Timothy L. Wiemken, Letizia Corinna Morlacchi, Fernandez Botran, R, Uriarte, S, Arnold, F, Rodriguez Hernandez, L, Rane, M, Peyrani, P, Wiemken, T, Kelley, R, Uppatla, S, Cavallazzi, R, Blasi, F, Morlacchi, L, Aliberti, S, Jonsson, C, Ramirez, J, and Bordon, J
- Subjects
Male ,community-acquired pneumonia ,Neutrophils ,Pneumonia severity index ,medicine.medical_treatment ,chemokines ,Gastroenterology ,Severity of Illness Index ,pneumonia severity ,0302 clinical medicine ,Patient Admission ,Community-acquired pneumonia ,Immunology and Allergy ,Prospective Studies ,Prospective cohort study ,0303 health sciences ,musculoskeletal, neural, and ocular physiology ,Middle Aged ,3. Good health ,Community-Acquired Infections ,Hospitalization ,Cytokine ,Female ,medicine.symptom ,medicine.medical_specialty ,Immunology ,Inflammation ,macromolecular substances ,Article ,03 medical and health sciences ,Internal medicine ,Severity of illness ,medicine ,Humans ,citokines, pneumonia, inflammation, CAP ,030304 developmental biology ,Aged ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,business.industry ,Sputum ,Pneumonia ,medicine.disease ,cytokines ,030228 respiratory system ,nervous system ,business - Abstract
The objective of this study was to compare systemic and local cytokine profiles and neutrophil responses in patients with severe versus non-severe community-acquired pneumonia (CAP). Hospitalized patients with CAP were grouped according to the pneumonia severity index (PSI), as non-severe (PSI
- Published
- 2014
47. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia
- Author
-
Martin Gnoni, Charles Feldman, Francesco Blasi, M. Raya, Jordi Rello, Stefano Aliberti, S. Figueroa, M. L. Rioseco, Jose Bordon, Aran Singanayagam, D. Pryluka, M. Barros, M. Riquelme, A. Torres, Heidi Lopez, R. Riquelme, P. Fernandez, J. Riquelme, Kwabena Ayesu, Y. Gomez, Alejandro J. Videla, Raul Nakamatsu, F. Saavedra, P. Alvare, Paula Peyrani, Lucia Marzoratti, Mohamed Saad, Tobias Welte, J. Guardiola, Guillermo Benchetrit, Timothy L. Wiemken, C. Contreras, Roberto Cosentini, Forest W Arnold, P. Jiménez, G. Arbo, James D. Chalmers, C. Inzunza, Gustavo Lopardo, Julio A. Ramirez, A. Klotchko, Riquelme, R, Jiménez, P, Videla, A, Lopez, H, Chalmers, J, Singanayagam, A, Riquelme, M, Peyrani, P, Wiemken, T, Arbo, G, Benchetrit, G, Rioseco, M, Ayesu, K, Klotchko, A, Marzoratti, L, Raya, M, Figueroa, S, Saavedra, F, Pryluka, D, Inzunza, C, Torres, A, Alvare, P, Fernandez, P, Barros, M, Gomez, Y, Contreras, C, Rello, J, Bordon, J, Feldman, C, Arnold, F, Nakamatsu, R, Riquelme, J, Blasi, F, Aliberti, S, Cosentini, R, Lopardo, G, Gnoni, M, Welte, T, Saad, M, Guardiola, J, and Ramirez, J
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pneumonia severity index ,Pneumonia, Viral ,medicine.disease_cause ,Severity of Illness Index ,Cohort Studies ,Influenza A Virus, H1N1 Subtype ,Risk Factors ,Internal medicine ,pneumonia, h1n1, influenza, mortality ,Influenza, Human ,Severity of illness ,medicine ,Influenza A virus ,Humans ,Obesity ,Respiratory sounds ,Intensive care medicine ,Aged ,Respiratory Sounds ,medicine.diagnostic_test ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,business.industry ,Mortality rate ,Middle Aged ,medicine.disease ,Community-Acquired Infections ,Hospitalization ,Pneumonia ,Infectious Diseases ,Blood pressure ,MED/17 - MALATTIE INFETTIVE ,Female ,business ,Forecasting ,Cohort study - Abstract
BACKGROUND: Community-acquired pneumonia (CAP) severity scores can identify patients at low risk for mortality who may be suitable for ambulatory care. Here, we follow the clinical course of hospitalized patients with CAP due to 2009 H1N1 influenza. OBJECTIVE: To evaluate the role of CAP severity scores as predictors of mortality. METHODS: This was a secondary data analysis of patients hospitalized with CAP due to 2009 H1N1 influenza confirmed by reverse transcriptase polymerase chain reaction enrolled in the CAPO (Community-Acquired Pneumonia Organization) international cohort study. CAP severity scores PSI (Pneumonia Severity Index), CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥ 65 years) and CRB-65 (confusion, respiratory rate, blood pressure, age ≥ 65 years) were calculated. Actual and predicted mortality rates were compared. A total of 37 predictor variables were evaluated to define those associated with mortality. RESULTS: Data from 250 patients with CAP due to 2009 H1N1 influenza were analyzed. Patients with low predicted mortality rates (0-1.5%) had actual mortality rates ranging from 2.6% to 17.5%. Obesity and wheezing were the only novel variables associated with mortality. CONCLUSIONS: The decision to hospitalize a patient with CAP due to 2009 H1N1 influenza should not be based on current CAP severity scores, as they underestimate mortality rates in a significant number of patients. Patients with obesity or wheezing should be considered at an increased risk for mortality. © 2011 The Union.
- Published
- 2011
48. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia
- Author
-
Francesco Blasi, Mehdi Mirsaeidi, Julio A. Ramirez, Giovanni Filardo, Paula Peyrani, Jose Bordon, Stefano Aliberti, Mirsaeidi, M, Peyrani, P, Aliberti, S, Filardo, G, Bordon, J, Blasi, F, and Ramirez, J
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Prognosi ,Kentucky ,Critical Care and Intensive Care Medicine ,Follow-Up Studie ,Community-acquired pneumonia ,Retrospective Studie ,Internal medicine ,medicine ,Pneumonia, Bacterial ,Platelet ,Community-Acquired Infection ,Hospital Mortality ,Aged ,Phagocytosi ,Thrombocytosis ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,business.industry ,Platelet Count ,Risk Factor ,Confounding ,Retrospective cohort study ,medicine.disease ,Platelet Activation ,Thrombocytopenia ,Survival Rate ,Hospitalization ,Pneumonia ,MED/17 - MALATTIE INFETTIVE ,Abnormal leukocyte count ,Immunology ,Thrombocytosi ,Female ,MED/09 - MEDICINA INTERNA ,Cardiology and Cardiovascular Medicine ,business ,Cohort study ,Human - Abstract
Background: Platelets are inflammatory cells with an important role in antimicrobial host defenses. We speculate that an abnormal platelet count may be a marker of severity in patients with community-acquired pneumonia (CAP). The objectives of this study were to evaluate if abnormal platelet count in hospitalized patients with CAP was associated with 30-day mortality and to compare platelet count and leukocyte count as predictors of 30-day mortality. Methods: We performed a retrospective cohort study of 500 consecutive patients hospitalized with CAP at the Veterans Hospital of Louisville, Kentucky, between June 2001 and March 2006 to investigate the association of platelet count and leukocyte count with 30-day mortality. Predictor variables were platelet count and leukocyte count. Abnormal platelet count was < 100,000/L (thrombocytopenia) and > 400,000/L (thrombocytosis). The outcome variable was 30-day mortality. To control for potential confounding, a propensity score that incorporated 33 variables was used. Results: Platelet count was strongly associated ( P = .0009) with 30-day mortality, whereas no association was observed for leukocyte count ( P = .5114). High platelet counts resulted in a significantly increased risk of mortality. Conclusions: Thrombocytopenia and thrombocytosis are associated with mortality in patients hospitalized with CAP. When evaluating an initial CBC test in patients with CAP, an abnormal platelet count is a better predictor of outcome than an abnormal leukocyte count. © 2010 American College of Chest Physicians.
- Published
- 2010
49. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia
- Author
-
Paula Peyrani, Asad Amir, Giovanni Filardo, Josh Gordon, Bryan K. Moffett, Francesco Blasi, Jose Bordon, Stefano Aliberti, Mehdi Mirsaeidi, Julio A. Ramirez, Ramirez, J, Aliberti, S, Mirsaeidi, M, Peyrani, P, Filardo, G, Amir, A, Moffett, B, Gordon, J, Blasi, F, and Bordon, J
- Subjects
Male ,Pneumonia severity index ,Myocardial Infarction ,Severity of Illness Index ,law.invention ,Community-acquired pneumonia ,law ,Retrospective Studie ,Risk Factors ,Medicine ,Community-Acquired Infection ,health care economics and organizations ,Aged, 80 and over ,Respiratory infection ,Shock ,Middle Aged ,Intensive care unit ,Community-Acquired Infections ,Hospitalization ,Infectious Diseases ,Female ,Respiratory Insufficiency ,Human ,Microbiology (medical) ,medicine.medical_specialty ,Hospitals, Veteran ,Logistic Model ,Hospitals, Veterans ,Kentucky ,Internal medicine ,Severity of illness ,Humans ,cardiovascular diseases ,Intensive care medicine ,Aged ,Retrospective Studies ,MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,business.industry ,Risk Factor ,MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,Pneumonia ,Length of Stay ,medicine.disease ,MED/17 - MALATTIE INFETTIVE ,Logistic Models ,Respiratory failure ,Myocardial infarction diagnosis ,MED/09 - MEDICINA INTERNA ,business - Abstract
Background An epidemiological link between respiratory infection and acute myocardial infarction (AMI) has been suggested, and recent data indicate that there is an association between AMI and pneumococcal community-acquired pneumonia (CAP) in hospitalized patients. The objective of this study was to investigate the association of AMI with the severity of pneumonia at hospitalization and clinical failure during hospitalization among patients with CAP. Methods An observational, retrospective study involving consecutive patients hospitalized with CAP was performed at the Veterans Hospital of Louisville, Kentucky. Patients admitted to the intensive care unit were defined as having severe CAP. Clinical failure was defined as the development of respiratory failure or shock. AMI was diagnosed on the basis of abnormal troponin levels and electrocardiogram findings. Propensity-adjusted models that controlled for clinical and nonclinical factors were used to investigate the association between AMI and pneumonia severity index and between AMI and clinical failure. Results Data for a total of 500 patients were studied. At hospital admission, AMI was present in 13 (15%) of 86 patients with severe CAP. During hospitalization, AMI was present in 13 (20%) of 65 patients who experienced clinical failure. Following risk adjustment, significant associations were discovered between AMI and the pneumonia severity index score (modeled with a restricted cubic spline) (P = .05) and between AMI and clinical failure (P = .04). Conclusions A combined diagnosis of CAP and AMI is common among hospitalized patients with severe CAP. In cases in which the clinical course of a hospitalized patient with CAP is complicated by clinical failure, AMI should be considered as a possible etiology.
- Published
- 2008
50. Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control.
- Author
-
Jain A, Canepa GE, Liou ML, Fledderman EL, Chapoval AI, Xiao L, Mukherjee I, Balogun BM, Huaman-Vergara H, Galvin JA, Kumar PN, Bordon J, Conant MA, and Boyle JS
- Abstract
Human Immunodeficiency Virus (HIV) remains a global health challenge, and novel approaches to improve HIV control are significantly important. The cell and gene therapy product AGT103-T was previously evaluated (NCT04561258) for safety, immunogenicity, and persistence in seven patients for up to 180 days post infusion. In this study, we sought to investigate the impact of AGT103-T treatment upon analytical treatment interruptions (ATIs). Six patients previously infused with AGT103-T were enrolled into an ATI study (NCT05540964), wherein they suspended their antiretroviral therapy (ART) until their viral load reached 100,000 copies/mL in two successive visits, or their CD4 count was reduced to below 300 cells/μL. During the ATI, all patients experienced viral rebound followed by a notable expansion in HIV specific immune responses. The participants demonstrated up to a five-fold increase in total CD8 counts over baseline approximately 1-2 weeks followed by the peak viremia. This coincided with a rise in HIV-specific CD8 T cells, which was attributed to the increase in antigen availability and memory recall. Thus, the protocol was amended to include a second ATI with the first ATI serving as an "auto-vaccination." Four patients participated in a second ATI. During the second ATI, the Gag-specific CD8 T cells were either maintained or rose in response to viral rebound and the peak viremia was substantially decreased. The patients reached a viral set point ranging from 7,000 copies/mL to 25,000 copies/mL. Upon resuming ART, all participants achieved viral control more rapidly than during the first ATI, with CD4 counts remaining within 10% of baseline measurements and without any serious adverse events or evidence of drug resistance. In summary, the rise in CD8 counts and the viral suppression observed in 100% of the study participants are novel observations demonstrating that AGT103-T gene therapy when combined with multiple ATIs, is a safe and effective approach for achieving viral control, with viral setpoints consistently below 25,000 copies/mL and relatively stable CD4 T cell counts. We conclude that HIV cure-oriented cell and gene therapy trials should include ATI and may benefit from designs that include multiple ATIs when induction of CD8 T cells is required to establish viral control., Competing Interests: Authors AJ, GC, M-LL, EF, AC, LX, IM, BB, HH-V, JG, MC, and JeB are shareholders and current employees of American Gene Technologies International, Inc. Authors PK and JoB received funding for the costs of the clinical trial from American Gene Technologies International, Inc., (Copyright © 2024 Jain, Canepa, Liou, Fledderman, Chapoval, Xiao, Mukherjee, Balogun, Huaman-Vergara, Galvin, Kumar, Bordon, Conant and Boyle.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.